Back to results
US 2017/0319676 A1Published application
Antifugetactic agents for the treatment of cancers
AssigneeThe General Hospital Corporation
InventorsMark C. Poznansky, John T. Potts, JR., Fabrizio Vianello, Natalia Papeta
Life of this patent
Estimating the term…
Abstract
This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides fugetactic agents and methods for the use thereof in enhancing an immune response.
Claims7
1-38. (canceled)
A method for increasing the migratory capacity of immune cells into a mammalian oral tumor exhibiting fugetactic activity on said immune cells due to CXCL12 secretion, wherein said immune cells comprise tumor antigen-specific T-cells, which method comprises:
- a) selecting a mammal having said tumor which secretes a fugetactic effective amount of CXCL12 around said tumor;
- b) contacting said T-cells with an anti-fugetactic concentration of 1,1′-[1,4-phenylenebis-(methylene)]bis[1,4,8,11-tetraazacyclotetradecane] of up to 5 μg/mL wherein said T-cells are now capable of increasing their migration into said tumor through the fugetactic activity of said tumor.
Dependencies are inferred from the claim text.